EZH2 and cancer: These agents encompass DNA methyltransferase (DNMT) inhibitors, which counteract abnormal DNA hypermethylation; histone deacetylase (HDAC) inhibitors, which facilitate the restoration of gene expression through histone acetylation; and histone methyltransferases such as EZH2 and DOT1L, which are often found to be dysregulated in various cancers.